Flexion Therapeutics Long Term Debt

Flexion Therapeutics (FLXN) currently reports a long-term debt of $250M as of September 2021. That compares with $210M in the prior-year period — up 20.0% year over year. Use the charts on this page to explore Flexion Therapeutics's long-term debt history and peer comparisons.

Flexion Therapeutics's long-term debt increased from $210M to $250M — a 20.0% year-over-year increase (period ending September 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Flexion Therapeutics reported $250M in long-term debt as of September 2021. That compares with $210M in the prior-year period — up 20.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $250M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Flexion Therapeutics, and consider following FLXN for alerts when major investors trade the stock.

Flexion Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $250M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FLXN with unrelated industries.